Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

Celularity Inc

Celularity Inc 27 Jul 2023
0

Celularity Inc. Announces $3 Million Registered Direct Offering

...
in
Press Releases
617
Celularity Inc 27 Jul 2023
0

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications

...
in
Press Releases
616
Celularity Inc 18 Jul 2023
0

Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies

...
in
Press Releases
604
Celularity Inc 29 Jun 2023
0

Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics

...
in
Press Releases
605
Celularity Inc 1 Jun 2023
0

Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability

...
in
Press Releases
593
Celularity Inc 23 May 2023
0

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
in
Press Releases
570
Celularity Inc 19 May 2023
0

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and...
in
Press Releases
589
Celularity Inc 10 May 2023
0

...
in
Press Releases
591
Celularity Inc 11 Mar 2023
0

Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders For Celularity Branded Halal-Certified Biomaterial Products

Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
in
Press Releases
569
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions

in
F.A.Q
Support Forum
Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: (908) 768 – 2170